Acta Neuropathologica Communications (May 2021)

Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice

  • Alejandro Ruiz-Riquelme,
  • Alison Mao,
  • Marim M. Barghash,
  • Heather H. C. Lau,
  • Erica Stuart,
  • Gabor G. Kovacs,
  • K. Peter R. Nilsson,
  • Paul E. Fraser,
  • Gerold Schmitt-Ulms,
  • Joel C. Watts

DOI
https://doi.org/10.1186/s40478-021-01187-6
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 19

Abstract

Read online

Abstract When injected into genetically modified mice, aggregates of the amyloid-β (Aβ) peptide from the brains of Alzheimer’s disease (AD) patients or transgenic AD mouse models seed cerebral Aβ deposition in a prion-like fashion. Within the brain, Aβ exists as a pool of distinct C-terminal variants with lengths ranging from 37 to 43 amino acids, yet the relative contribution of individual C-terminal Aβ variants to the seeding behavior of Aβ aggregates remains unknown. Here, we have investigated the relative seeding activities of Aβ aggregates composed exclusively of recombinant Aβ38, Aβ40, Aβ42, or Aβ43. Cerebral Aβ42 levels were not increased in App NL−F knock-in mice injected with Aβ38 or Aβ40 aggregates and were only increased in a subset of mice injected with Aβ42 aggregates. In contrast, significant accumulation of Aβ42 was observed in the brains of all mice inoculated with Aβ43 aggregates, and the extent of Aβ42 induction was comparable to that in mice injected with brain-derived Aβ seeds. Mice inoculated with Aβ43 aggregates exhibited a distinct pattern of cerebral Aβ pathology compared to mice injected with brain-derived Aβ aggregates, suggesting that recombinant Aβ43 may polymerize into a unique strain. Our results indicate that aggregates containing longer Aβ C-terminal variants are more potent inducers of cerebral Aβ deposition and highlight the potential role of Aβ43 seeds as a crucial factor in the initial stages of Aβ pathology in AD.

Keywords